JAKAVI — Total revenues
Incyte JAKAVI — Total revenues decreased by 18.9% to $105.60M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 14.7%, from $92.10M to $105.60M. Over 3 years (FY 2021 to FY 2025), JAKAVI — Total revenues shows an upward trend with a 10.6% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
Higher revenue indicates strong market adoption and effective commercialization, while declining revenue may signal increased competition or patent expiration.
Detailed definition
This metric captures the total gross revenue generated by a specific pharmaceutical product or therapeutic segment withi...
Peer comparison
Standard revenue reporting for individual drug franchises; peers report this to demonstrate the scale and health of their core therapeutic portfolios.
incy_segment_jakavi_total_revenuesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $82.00M | $94.70M | $95.70M | $70.80M | $83.60M | $76.70M | $90.40M | $96.60M | $103.90M | $89.60M | $99.30M | $115.70M | $114.10M | $92.10M | $109.70M | $125.60M | $130.20M | $105.60M |
| QoQ Change | — | +15.5% | +1.1% | -26.0% | +18.1% | -8.3% | +17.9% | +6.9% | +7.6% | -13.8% | +10.8% | +16.5% | -1.4% | -19.3% | +19.1% | +14.5% | +3.7% | -18.9% |
| YoY Change | — | — | — | — | +2.0% | +8.3% | +8.1% | — | — | +16.8% | +9.8% | +19.8% | +9.8% | +2.8% | +10.5% | +8.6% | +14.1% | +14.7% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Incyte's jakavi — total revenues?
- Incyte (INCY) reported jakavi — total revenues of $105.60M in Q1 2026.
- How has Incyte's jakavi — total revenues changed year-over-year?
- Incyte's jakavi — total revenues increased by 14.7% year-over-year, from $92.10M to $105.60M.
- What is the long-term trend for Incyte's jakavi — total revenues?
- Over 3 years (2021 to 2025), Incyte's jakavi — total revenues has grown at a 10.6% compound annual growth rate (CAGR), from $338.00M to $457.60M.
- What does jakavi — total revenues mean?
- The total sales revenue generated by a specific drug product in a given market.